Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high─risk CSCC in phase 3 trial

Press/Media

Period	15 Jan 2025

Media coverage

Title	Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high─risk CSCC in phase 3 trial
Media name/outlet	PharmaBiz
Country/Territory	India
Date	15/01/25
URL	https://pharmabiz.com/ArticleDetails.aspx?aid=174719&sid=2
Persons	Israel Lowy,

Title	Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial
Media name/outlet	PharmaBiz
Country/Territory	India
Date	15/01/25
URL	https://www.pharmabiz.com/NewsDetails.aspx?aid=174719&sid=2
Persons	Israel Lowy,